The simultaneous ability to selectively inhibit BChE (without noticeable suppression of the AChE activity) and block the ifenprodil-binding site of NMDA receptors found for some new compounds (С-1a, C-2e, C-2f, and C-2h) may substantially enhance the general therapeutic effect in the treatment of AD and as well as related diseases. This evidence concerns the gene ACHE and Alzheimer disease.